Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

ASO Visual Abstract: Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial.

Annals of surgical oncology·2025

Same author

Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer.

ESMO open·2025

Same author

Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.

Breast cancer research : BCR·2025

Same author

Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109).

ESMO open·2025

Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 26, 2026

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

HER2 imaging in the ZEPHIR study

A S Clark¹, A DeMichele², D Mankoff³

¹Department of Medicine, Division of Hematology/Oncology, Abramson Cancer Center amy.clark@uphs.upenn.edu.

Annals of Oncology : Official Journal of the European Society for Medical Oncology

|January 24, 2016

Summary

No abstract available in PubMed .

More Related Videos

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Determining Binding Affinity KD of Radiolabeled Antibodies to Immobilized Antigens

Determining Binding Affinity KD of Radiolabeled Antibodies to Immobilized Antigens

Published on: June 23, 2022

Related Experiment Videos

Last Updated: Mar 26, 2026

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Determining Binding Affinity KD of Radiolabeled Antibodies to Immobilized Antigens

Determining Binding Affinity KD of Radiolabeled Antibodies to Immobilized Antigens

Published on: June 23, 2022